P2RY12 and atrial fibrillation: Currently, there are several RCT being conducted to assess the efficacy and safety of DOACs and new P2Y12 inhibitor-based regimen including AUGUSTUS with apixaban, ENTRUST-AF PCI with edoxaban and MANJUSRI with ticagrelor (Lu et al., 2015; Vranckx et al., 2018).